Prilenia Therapeutics
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Naarden, North Holland, NetherlandsWebsite
www.prilenia.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Prilenia Therapeutics
Prilenia Therapeutics is a clinical stage biotech company focused on developing treatments for Huntington's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative and neurodevelopmental disorders. The company aims to address the urgent needs of patients and their families by advancing potential treatments, particularly through their research on pridopidine. Prilenia harnesses the brain's neuroprotective capabilities, specifically targeting the sigma-1 receptor to restore impaired pathways. Their mission is to change lives through innovation and collaboration, inviting individuals to join their efforts in making a difference.Explore more
Prilenia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prilenia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Prilenia Therapeutics recently announced quarterly report
Check if Prilenia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Prilenia Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Prilenia Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Prilenia Therapeutics launches new products
Prilenia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Prilenia Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Prilenia Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Prilenia Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Prilenia Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Prilenia Therapeutics.
Prilenia Therapeutics financials insights
Gather financial insights about Prilenia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$62.5M
2021
Series B
$43M
Prilenia Therapeutics Tech Stack
A closer look at the technologies used by Prilenia Therapeutics
Most Recent Scoops
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Prilenia Therapeutics News & Media
Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer - Rutland Herald
NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Apr 28, 2026--Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer - Finanznachrichten
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and AmyotrophicPrilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a po
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prilenia Therapeutics
Sign Up For FreeTo access detailed company insights
Prilenia Therapeutics is a clinical stage biotech company focused on developing treatments for Huntington's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative and neurodevelopmental disorders. The company aims to address the urgent needs of patients and their families by advancing potential treatments, particularly through th... Read More
